Proline-rich polypeptide complex for use in treatment of bdnf-dependent disorders

a polypeptide complex and bdnf-dependent technology, applied in the field of proline-rich polypeptide complexes, can solve the problems of unknown mechanism underlying the alleged neuroprotective effect of prps in alzheimer's disease, and achieve the effects of supporting the development of the nervous system, increasing the bdnf level in the blood, and activating immunomodulatory activity

Inactive Publication Date: 2018-02-08
GEO POLAND
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025]BDNF level is highly associated with the immune deficiency syndrom, including human immunodeficiency virus (HIV). It has been shown that memantine, which has been recently approved for the treatment of Alzheimer's disease, prevented onset of cognitive deficits in the brain and this effect was correlated with the memantine-mediated upregulation of BDNF expression. Moreover, increased expression of BDNF within the brain led to the enhancement of dopamine and serotonine concentration in the brain. Thus, BDNF synthesis is regardered as an anti-depressant activity. Several data showed that inflammation accompanied by exaggerated pro-inflammatory cytokine production have been implicated in the pathogenesis of depression-like behaviour. In these conditions, BDNF level is strongly reduced in selected areas of the brain, accelerating depression-like symptoms. Thus, treating depression patients with BDNF constitute an effective therapy of mood-related neuropsychiatric diseases.
[0051]Further aspect of the present invention provides Proline-Rich Polypeptide complex for use as a nutritional additive for older babies after breastfeeding and / or after milk formula feeding, and for adults, in order to induce and / or enhance the activity of nervous system and / or to achieve the pro-cognitive effect, ie. the memory and concentration improvement.

Problems solved by technology

However, the mechanism underlying alleged neuroprotective effects of PRPs in Alzheimer's disease is still unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Proline-rich polypeptide complex for use in treatment of bdnf-dependent disorders
  • Proline-rich polypeptide complex for use in treatment of bdnf-dependent disorders
  • Proline-rich polypeptide complex for use in treatment of bdnf-dependent disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Pharmaceutical Composition (Tablets):

[0111]

IngredientmgCOLOCO prp0.12Lactose monohydrate DC100.00Lactose 200 mesh70.86Sorbitol270.00Microcrystalline cellulose69.00Xanthan gum6.00Vanilla flavour6.00Silicon dioxide3.00Magnesium stearate5.00Total530.00

Total weight of a tablet containing the following ingredients is 530 mg.

Infant Milk Formula Stage 1 Enriched with COLOCO Prp (GM-1C)

Formula milk stage 1 is an infant formula for babies 0-5 months, commercially available MAMI LAC 1, supplemented with COLOCO prp in the amount of 20 μg per 100 mg of the milk formula powder, providing the dose of COLOCO prp 2.7 μg per 100 ml of the ready to drink product.

Per 100 ml of readyCompositionto drink product100 gEnergykcal69510kJ2902140Fat:g3.525.5Linoleic acidmg4503300α-linolenic acidmg61450Protein:g1.289.5Caseing0.513.8Whey-proteing0.775.7Carbohydrates:g8.260.6Lactoseg7.454.8Maltodextring0.85.8Moisture Vitamins:g3.0Vit. Aμg85630Vit. D3μg1.410.5Vit. Emg1.18.1Vit. K1μg4.130Vit. Cmg8.160Vit. B1μg58430...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightsaaaaaaaaaa
obesity-related aaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention relates to the Proline-Rich Polypeptide complex (PRP) derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurotrophic Factor level as well as modulation thereof, particularly disorders and conditions wherein therapeutic strategy is based on the increasing of the BDNF concentration in blood.The PRP complex is postulated to be used for nutrition of adults, young children / babies and infants to promote and preserve the proper development and function of both immune and nervous system. PRPs may be used for supplementation of modified milk and infant milk formulae to make it closer to breast milk.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the Proline-Rich Polypeptide complex derived from the mammalian colostrum for use in the treatment of the disorders and conditions related to the alterations of the Brain-Derived Neurothropic Factor level as well as modulation thereof. In particular, the invention concerns the use of the Proline-Rich Polypeptide complex in the prophylactic and auxiliary treatment of the disorders and conditions responding to the increase of BDNF levels.[0002]Proline-Rich Polypeptide complex is intended to be used for nutrition of adults, young children / babies and infants to promote the proper development and function of both immune and nervous system. Furthermore, the complex could be used for the supplementation of the infant milk formula thus making it closer to breast milk.BACKGROUND OF THE INVENTION[0003]It has been well documented in the art that mammalian colostrum is a rich source of health-enhancing components including the immune ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/20A23L33/18A23L33/00A23C9/20
CPCA61K35/20A23C9/206A23L33/18A23L33/40A61P1/00A61P1/14A61P25/00A61P25/02A61P25/06A61P25/14A61P25/16A61P25/18A61P25/22A61P25/24A61P25/26A61P25/28A61P27/02A61P27/06A61P3/02A61P3/04A61P31/18A61P37/02A61P43/00A61P5/00A61P9/00A61P9/10A61P3/10A61K38/1709A23V2200/322A23V2002/00
Inventor DOBRZYNSKI, WLODZIMIERZ PIOTRBEDNAREK, MAGDALENA ANNA
Owner GEO POLAND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap